Acute myeloid leukemia is a blood cancer but, for many patients, the cancer may originate from an unusual source: a mutation in their bone cells.
Maternal coffee consumption during pregnancy is associated with increased risk of childhood acute leukemia.
Cytogenetic and molecular abnormalities may also be prognostic of post-relapse prognosis.
High-throughput sensitivity assay may make “personalized” therapy possible in relapsed or refractory AML.
Clinical practices does not always reflect evidence-based expert opinion when it comes to management of acute or chronic myeloid leukemia (AML, CML) and B-cell lymphomas.
Adding gemtuzumab ozogamicin to standard therapy improved event-free survival improved in children with de novo acute myeloid leukemia.
Results from a new study could benefit some children with high-risk AML. A therapeutic regimen that combined the GO with conventional three-drug chemotherapy was associated with improved survival in children with AML who underwent bone marrow transplantation.
The FDA has granted Breakthrough Therapy designation to volasertib (Boehringer Ingelheim) for the treatment of patients ≥65 years old with previously untreated acute myeloid leukemia (AML), ineligible for intensive remission induction therapy.